No headlines found.
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
Globe Newswire (Wed, 19-Aug 7:00 AM ET)
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
Globe Newswire (Tue, 18-Aug 7:00 AM ET)
Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier Program
PRNewswire (Thu, 13-Aug 4:15 PM ET)
PRNewswire (Wed, 5-Aug 8:01 AM ET)
Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
Globe Newswire (Wed, 15-Jul 7:00 AM ET)
PRNewswire (Mon, 13-Jul 8:01 AM ET)
PRNewswire (Mon, 6-Jul 9:25 AM ET)
PRNewswire (Fri, 26-Jun 8:01 AM ET)
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
PRNewswire (Wed, 10-Jun 4:15 PM ET)
PRNewswire (Tue, 2-Jun 8:01 AM ET)
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
Aethlon Medical trades on the NASDAQ stock market under the symbol AEMD.
As of August 28, 2026, AEMD stock price climbed to $2.49 with 27,238,492 million shares trading.
AEMD has a beta of 6.29, meaning it tends to be more sensitive to market movements. AEMD has a correlation of 0.12 to the broad based SPY ETF.
AEMD has a market cap of $1.77 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AEMD traded as high as $234.40 and as low as $.53.
AEMD has underperformed the market in the last year with a price return of -87.8% while the SPY ETF gained +19.7%. AEMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.3% and -12.0%, respectively, while the SPY returned +2.2% and -0.9%, respectively.
AEMD support price is $2.00 and resistance is $2.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEMD shares will trade within this expected range on the day.
